These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25039748)

  • 1. Quantification of rare NPM1 mutation subtypes by digital PCR.
    Bacher U; Dicker F; Haferlach C; Alpermann T; Rose D; Kern W; Haferlach T; Schnittger S
    Br J Haematol; 2014 Dec; 167(5):710-4. PubMed ID: 25039748
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid and highly specific screening for NPM1 mutations in acute myeloid leukemia.
    Oppliger Leibundgut E; Porret NA; Bienz Muggli M; Baumgartner H; Dahlhaus M; Baerlocher GM
    Ann Hematol; 2013 Jan; 92(2):173-7. PubMed ID: 23161387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
    Dvorakova D; Racil Z; Jeziskova I; Palasek I; Protivankova M; Lengerova M; Razga F; Mayer J
    Am J Hematol; 2010 Dec; 85(12):926-9. PubMed ID: 20981679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NPM1 for MRD? Droplet Like It's Hot!
    Wertheim GBW; Bagg A
    J Mol Diagn; 2017 Jul; 19(4):498-501. PubMed ID: 28645444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
    Krönke J; Schlenk RF; Jensen KO; Tschürtz F; Corbacioglu A; Gaidzik VI; Paschka P; Onken S; Eiwen K; Habdank M; Späth D; Lübbert M; Wattad M; Kindler T; Salih HR; Held G; Nachbaur D; von Lilienfeld-Toal M; Germing U; Haase D; Mergenthaler HG; Krauter J; Ganser A; Göhring G; Schlegelberger B; Döhner H; Döhner K
    J Clin Oncol; 2011 Jul; 29(19):2709-16. PubMed ID: 21555683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor.
    Papadaki C; Dufour A; Seibl M; Schneider S; Bohlander SK; Zellmeier E; Mellert G; Hiddemann W; Spiekermann K
    Br J Haematol; 2009 Feb; 144(4):517-23. PubMed ID: 19055671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations.
    Mencia-Trinchant N; Hu Y; Alas MA; Ali F; Wouters BJ; Lee S; Ritchie EK; Desai P; Guzman ML; Roboz GJ; Hassane DC
    J Mol Diagn; 2017 Jul; 19(4):537-548. PubMed ID: 28525762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant Enrichment with 3'-Modified Oligonucleotides (MEMO)-Quantitative PCR for Detection of NPM1 Mutations in Acute Myeloid Leukemia.
    Shin SY; Ki CS; Kim HJ; Kim JW; Kim SH; Lee ST
    J Clin Lab Anal; 2015 Sep; 29(5):361-5. PubMed ID: 25384962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
    Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
    Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of methods for detection of NPM1 gene mutations in acute myeloid leukemia].
    Li ZP; Zhang X; Zhao XM; Li QG; Chen YM; Lu QY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):999-1004. PubMed ID: 21867632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping.
    Thiede C; Creutzig E; Illmer T; Schaich M; Heise V; Ehninger G; Landt O
    Leukemia; 2006 Oct; 20(10):1897-9. PubMed ID: 17041639
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.
    Gorello P; Cazzaniga G; Alberti F; Dell'Oro MG; Gottardi E; Specchia G; Roti G; Rosati R; Martelli MF; Diverio D; Lo Coco F; Biondi A; Saglio G; Mecucci C; Falini B
    Leukemia; 2006 Jun; 20(6):1103-8. PubMed ID: 16541144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression.
    Kristensen T; Møller MB; Friis L; Bergmann OJ; Preiss B
    Eur J Haematol; 2011 Nov; 87(5):400-8. PubMed ID: 21707751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of the NPM1 gene contributes to the development of donor cell-derived acute myeloid leukemia after unrelated cord blood transplantation for acute lymphoblastic leukemia.
    Rodríguez-Macías G; Martínez-Laperche C; Gayoso J; Noriega V; Serrano D; Balsalobre P; Muñoz-Martínez C; Díez-Martín JL; Buño I
    Hum Pathol; 2013 Aug; 44(8):1696-9. PubMed ID: 23465275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.
    Guolo F; Minetto P; Clavio M; Miglino M; Colombo N; Cagnetta A; Cea M; Marcolin R; Todiere A; Ballerini F; Gobbi M; Lemoli RM
    Br J Haematol; 2019 Sep; 186(6):e223-e225. PubMed ID: 31348524
    [No Abstract]   [Full Text] [Related]  

  • 17. Quantitative detection of circulating nucleophosmin mutations DNA in the plasma of patients with acute myeloid leukemia.
    Quan J; Gao YJ; Yang ZL; Chen H; Xian JR; Zhang SS; Zou Q; Zhang L
    Int J Med Sci; 2015; 12(1):17-22. PubMed ID: 25552914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
    Abdelhamid E; Preudhomme C; Helevaut N; Nibourel O; Gardin C; Rousselot P; Castaigne S; Gruson B; Berthon C; Soua Z; Renneville A
    Leuk Res; 2012 Mar; 36(3):316-23. PubMed ID: 22129478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two novel NPM1 mutations in an acute myeloid leukemia patient transformed from primary myelofibrosis.
    Park SH; Chi HS; Shim H; Jang S; Park CJ
    Int J Lab Hematol; 2013 Feb; 35(1):e1-3. PubMed ID: 22978565
    [No Abstract]   [Full Text] [Related]  

  • 20. Multiplex high-throughput gene mutation analysis in acute myeloid leukemia.
    Dunlap J; Beadling C; Warrick A; Neff T; Fleming WH; Loriaux M; Heinrich MC; Kovacsovics T; Kelemen K; Leeborg N; Gatter K; Braziel RM; Press R; Corless CL; Fan G
    Hum Pathol; 2012 Dec; 43(12):2167-76. PubMed ID: 22658276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.